The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Inclusion Criteria:

• Male or female subjects 18-60 years allergic to ragweed pollen.
• Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit.

Exclusion Criteria:

• Subjects with significant diseases other than allergic rhinitis that may interfere with the safety or efficacy of PF-03654764.
• Subjects with significant symptoms of allergic rhinitis within the 2 weeks prior to screening.